Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• He Y, Zheng R, Li D, et al. Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res. 2015;27:29–37.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Li X, Ma T, Zhang Q, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Lett. 2017;406:22–26.
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–1057.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.
   PubMedGoogle Scholar
• Suker M, Beumer BR, Sadot E, et al. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Lancet Oncol. 2016;17:801–810.
   PubMed Web of Science ®Google Scholar
• Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. Cancer Treat Rev. 1975;2:193–214.
   PubMed Web of Science ®Google Scholar
• Oster MW, Robert G, Lawrence P, et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer. 1986;57:29–33.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607–620.
   PubMed Web of Science ®Google Scholar
• Burris HA3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• DeCaprio JA, Mayer RJ, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991;9:2128–2133.
   PubMed Web of Science ®Google Scholar
• Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 1991;9:1682–1686.
   PubMed Web of Science ®Google Scholar
• Huguet F, Girard N, Guerche CS-E, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27:2269–2277.
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607–2615.
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial E2297. J Clin Oncol. 2002;20:3270–3275.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–2217.
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952.
   PubMed Web of Science ®Google Scholar
• Lima CMR, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28:3617–3622.
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group–directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–3610.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–1648.
   PubMed Web of Science ®Google Scholar
• Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer–a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study. J Clin Oncol. 2005;23:1228–1236.
   PubMed Web of Science ®Google Scholar
• Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–1315.
   PubMed Web of Science ®Google Scholar
• Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2012;30:361.
   PubMed Web of Science ®Google Scholar
• Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:809.
   PubMed Web of Science ®Google Scholar
• Chllamma MK, Cook N, Dhani NC, et al. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115:649.
   PubMed Web of Science ®Google Scholar
• Moorcraft SY, Khan K, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13:232–238.
   PubMed Web of Science ®Google Scholar
• Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001;17:1–18.
   PubMed Web of Science ®Google Scholar
• Senior K. Hyperthermia and hypoxia for cancer-cell destruction. Lancet Oncol. 2001;2:524.
   Web of Science ®Google Scholar
• Hiraoka M, Jo S, Akuta K, et al. Radiofrequency capacitive hyperthermia for deep-seated tumors. II. Effects of thermoradiotherapy. Cancer. 1987;60:128–135.
   PubMed Web of Science ®Google Scholar
• Hornback NB. Historical aspects of hyperthermia in cancer therapy. Radiol Clin North Am. 1989;27:481–488.
   PubMed Web of Science ®Google Scholar
• Rau B, Wust P, Hohenberger P, et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg. 1998;227:380–389.
   PubMed Web of Science ®Google Scholar
• Qing Yu F, Bao An M, Xiu Chun Q, et al. Preliminary report on treatment of bone tumors with microwave‐induced hyperthermia. Bioelectromagnetics. 1996;17:218–222.
   PubMed Web of Science ®Google Scholar
• Fan YF, Qin Y, Li DG, et al. Retrospective clinical study of advanced pancreatic cancer treated with chemotherapy and abdominal hyperthermia. J Glob Oncol. 2018;4:1–4.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463–468.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kokura S, Oyamada H, et al. Effects of a sequential combination of hyperthermia and gemcitabine in the treatment of advanced unresectable pancreatic cancer: a retrospective study. Thermal Med. 2008;24:131–139.
   Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11:561–570.
   PubMed Web of Science ®Google Scholar
• Lagendijk JJW, Van Rhoon GC, Hornsleth SN, et al. Esho quality assurance guidelines for regional hyperthermia. Int J Hyperthermia. 1998;14:125–133.
   PubMed Web of Science ®Google Scholar
• Tschoep-Lechner KE, Milani V, Berger F, et al. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia. 2013;29:8–16.
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Chen H, et al. Hyperthermia as an adjuvant therapy to chemotherapy for the treatment of advanced ovarian cancer complicated by ascites. Biomed Res. 2017;28:8115–8120.
   Google Scholar
• Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481–489.
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Yano K, Seo Y, et al. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anti-Cancer Drugs. 1995;6:413–418.
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5:1189–1196.
   PubMed Web of Science ®Google Scholar
• Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998;42:391–399.
   PubMed Web of Science ®Google Scholar
• Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol. 1998;56:1315–1322.
   PubMed Web of Science ®Google Scholar
• Mans DRA, Grivicich I, Peters GJ, et al. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer. 1999;35:1851–1861.
   PubMed Web of Science ®Google Scholar
• Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80:301–306.
   PubMed Web of Science ®Google Scholar
• Lee MG, Lee SH, Lee SJ, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy. 2013;59:273–279.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–1097.
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–1281.
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23–44.
   PubMed Web of Science ®Google Scholar
• Ozaka M, Matsumura Y, Ishii H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol. 2012;69:1197–1204.
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18:335–348.
   PubMed Web of Science ®Google Scholar
• Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.
   PubMed Web of Science ®Google Scholar
• Rietbroek R, Van De Vaart P, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123:6–12.
   PubMed Web of Science ®Google Scholar
• Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia. 2002;18:307–315.
   PubMed Web of Science ®Google Scholar
• Kondo T, Ueda K, Kano E. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Res. 1995;15:83–86.
   PubMed Web of Science ®Google Scholar
• Katschinski DM, Robins HI. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity. Int J Cancer. 1999;80:104–109.
   PubMed Web of Science ®Google Scholar
• Urano M, Kahn J, Reynolds R. The effect of 5-fluorouracil at elevated temperatures on a spontaneous mouse tumour: arrhenius analysis and tumour response. Int J Radiat Biol. 1991;59:239–249.
   PubMed Web of Science ®Google Scholar
• Monge OR. Rofstad EKKaalhus O thermochemotherapy in vivo of a C3H mouse mammary carcinoma: single fraction heat and drug treatment. Eur J Cancer Clin Oncol. 1988;24:1661–1669.
   PubMedGoogle Scholar
• Takemoto M, Kuroda M, Urano M, et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia. 2003;19:193–203.
   PubMed Web of Science ®Google Scholar
• Kido Y, Kuwano H, Maehara Y, et al. Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia. Cancer Chemother Pharmacol. 1991;28:251–254.
   PubMed Web of Science ®Google Scholar
• Mini E, Dombrowski J, Moroson BA, et al. Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-Lymphoblast cell line, CCRF-CEM. Eur J Cancer Clin Oncol. 1986;22:927–934.
   PubMedGoogle Scholar
• Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–497.
   PubMed Web of Science ®Google Scholar
• Olch AJ, Kaiser LR, Silberman AW, et al. Blood flow in human tumors during hyperthermia therapy: demonstration of vasoregulation and an applicable physiological model. J Surg Oncol. 1983;23:125–132.
   PubMed Web of Science ®Google Scholar
• Song CW, Shakil A, Osborn JL, et al. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia. 1996;12:367–373.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465.
   PubMed Web of Science ®Google Scholar
• Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res. 2001;155:515–528.
   PubMed Web of Science ®Google Scholar
• Jones EL, Prosnitz LR, Dewhirst MW, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res. 2004;10:4287–4293.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2012;18:4249–4256.
   PubMed Web of Science ®Google Scholar
• Oei AL, Ahire VR, van Leeuwen CM, et al. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i. Int J Hyperthermia. 2018;34:39–48.
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Oguro S, et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013;8:e55146.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Z, Mi DH, et al. Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis. J Clin Pharm Ther. 2017;42:155–164.
   PubMed Web of Science ®Google Scholar
• Roesch M, Mueller-Huebenthal B. Review: the role of hyperthermia in treating pancreatic tumors. Indian J Surg Oncol. 2015;6:75–81.
   PubMed Web of Science ®Google Scholar
• Pestieau SR, Stuart OA, Chang D, et al. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 1998;84:706–711.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Krawczyk PM, et al. Targeting therapy-resistant cancer stem cells by hyperthermia. Int J Hyperthermia. 2017;33:419–427.
   PubMed Web of Science ®Google Scholar